Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Mesoblast Limited — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.83 (market cap $173.62M), while Mesoblast Limited trades at $14.3 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 10.1× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Mesoblast Limited is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Mesoblast Limited for 15 Days on average.
| CWEB | MESO | |
|---|---|---|
Market Cap | $173.62M | $1.75B |
Volume | 551,726 | 239,027 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $20.96 |
52-Week Low | $17.39 | $13.19 |
Typical Hold Time | 24 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.
The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
